Phase 2 N=58 A Novel Pharmacological Therapy for Obstructive Sleep Apnea
Sleep Apnea
Primary: Apnea-hypopnea Index [AHI] — -11.8; -2.3 events/hr; % change from baseline
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=507 A Study of Hookah Café Customers in the Atlanta Area
Waterpipe Tobacco Smoking
Primary: Change in Expired Carbon Monoxide (eCO Boost) — 25.7; 23.5 parts per million
N/A N=20 NewGait: A Low-Cost Rehabilitation System to Improve Post-Stroke Gait (Biomechanical Adaptations)
Stroke
Primary: Gait Speed — 0.90; 0.92; 0.88; 0.87 meters per second — p=0.894
N/A N=50 Evaluation of the Effectiveness of Calcium Phosphate Containing Desensitizer on Postoperative Sensitivity
Postoperative Pain
Primary: Visual Analog Scale (VAS) — 0.4; 1.3 cm on a 10-point Visual Analogue Scale
N/A N=15 The Impact of Exercise on Subthalamic Nucleus Neural Activity in Parkinson's Disease
Parkinson Disease · Deep Brain Stimulation
Primary: Finger Tapping — 3; 3; 3; 3 score on a scale
Phase 2 N=125 Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Non-alcoholic Steatohepatitis
Primary: Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) — -32.9; -10.4 percent…
Phase 2 N=47 Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
Mesothelioma; Lung
Primary: To Evaluate the Efficacy of the Treatment — 1.9 Months
Phase 1 N=28 Relative Bioavailability of Evobrutinib Tablet Batches
Healthy
Primary: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib — 198; 164; 207; 205 hour×nanogram per milliliter…
Phase 3 N=101 A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
Inherited Mitochondrial Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 91 Participants
Phase 2 N=16 PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Acute Leukemia · Myelodysplastic Syndromes · Myeloproliferative Neoplasm
Primary: Determine the Optimal Dose of VIC-1911 When Given in Combination With Standard Immunosuppressive Therapy in Adult Patients Undergoing Myeloablative Stem Cell…
N/A N=129 Efficacy of Two Sonic Toothbrushes in Reducing Extrinsic Tooth Stain
Tooth Bleaching
Primary: Lobene Stain Index of Stain Intensity Scores 4 Weeks After Toothbrush Use — 0.89; 0.88; 1.13 score on a scale
N/A N=168 Impact of Community Health Workers on Adherence to Therapy for Non-Communicable Chronic Disease in Chiapas, Mexico
Hypertension · Diabetes Mellitus, Type 2
Primary: Change in Hemoglobin A1c — -0.35 percentage of glycated hemoglobin
N/A N=26 Spinal Cord Injury Exercise and Nutrition Conceptual Engagement
Spinal Cord Injuries · Metabolic Syndrome · Dietary Modification
Primary: Percent Body Fat Assessed by DXA at Baseline and 21 Weeks — 26.6; 25.9; 22.0; 25.6 % of body fat
Phase 1 N=42 A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B
Healthy Study Participants
Primary: Maximum Plasma Concentration (Cmax) of UCB0599 in Part A — 876.2; 724.6; 618.0; 449.3 nanograms per milliliter (ng/mL)
N/A N=3,028 School Based Program to Prevent Teen Dating Violence
Violence
Primary: Number of Participants With Perpetration of Physical Teen Dating Violence (TDV) — 58; 103 Participants — p=0.05